Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;68(7):e28975.
doi: 10.1002/pbc.28975. Epub 2021 Mar 4.

Children and young adults hospitalized for severe COVID-19 exhibit thrombotic coagulopathy

William B Mitchell  1 , Jennifer Davila  1 , Janine Keenan  1 , Jenai Jackson  1 , Adit Tal  1 , Kerry A Morrone  1 , Ellen J Silver  2 , Sarah O'Brien  3 , Deepa Manwani  1
Affiliations

Children and young adults hospitalized for severe COVID-19 exhibit thrombotic coagulopathy

William B Mitchell et al. Pediatr Blood Cancer. 2021 Jul.

Abstract

We report the clinical and laboratory coagulation characteristics of 27 pediatric and young adult patients (2 months to 21 years) treated for symptomatic COVID-19 at a children's hospital in the Bronx, New York, between March 1 and May 31, 2020. D-Dimer was > 0.5 μg/mL (upper limit of normal) in 25 (93%) patients at admission; 11 (41%) developed peak D-dimer > 5 μg/mL during admission. Seven (26%) patients developed venous thromboembolism: three with deep vein thrombosis and four with pulmonary embolism. Requirement of increased ventilatory support was a risk factor for thrombosis (P = 0.006). Three of eight (38%) patients on prophylactic anticoagulation developed thrombosis; however, no patients developed VTE on low-molecular-weight heparin prophylaxis titrated to anti-Xa level. Manifestation of COVID-19 disease was severe or critical in 16 (59%) patients. Four (15%) patients died of COVID-19 complications: all had comorbidities. Elevated D-dimer and increased VTE rate were observed in this young cohort, particularly in those with severe respiratory complications, suggesting thrombotic coagulopathy. More data are needed to guide thromboprophylaxis in this age group.

Keywords: COVID-19; SARS-Co-V2; pediatric; thrombosis; venous thromboembolism; young adult.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial conflicts.

References

    1. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS‐CoV‐2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089‐1098. 10.1007/s00134-020-06062-x. - DOI - PMC - PubMed
    1. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease. Crit Care Med. 2020;48(9):1358‐1364. 10.1097/ccm.0000000000004458. - DOI - PMC - PubMed
    1. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID‐19. J Thromb Haemost. 2020;18(9):2103‐2109. 10.1111/jth.14975. - DOI - PMC - PubMed
    1. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID‐19. Inflamm Res. 2020;69(12):1181‐1189. 10.1007/s00011-020-01401-6. - DOI - PMC - PubMed
    1. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in children and adolescents: a systematic review. JAMA Pediatrics. 2020;174(9):882‐889. 10.1001/jamapediatrics.2020.1467. - DOI - PubMed

MeSH terms